Transitional Cell Cancer of the Renal Pelvis and Ureter Completed Phase 2 Trials for Sunitinib (DB01268)

Also known as: Transitional Cell Cancer of Renal Pelvis and Ureter / Transitional Cell Tumor / Transitional cell carcinoma of upper urinary tract (disorder) / Transitional cell cancer of the renal pelvis and ureter NOS / Renal pelvis and ureter transitional cell cancer NOS / Renal pelvis and ureteric cancer NOS transitional cell / Renal pelvis and ureteral cancer transitional cell NOS / Renal pelvis and ureteric cancer transitional cell NOS

IndicationStatusPhase
DBCOND0028512 (Transitional Cell Cancer of the Renal Pelvis and Ureter)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01089088Gemcitabine Hydrochloride, Cisplatin, and Sunitinib Malate as First-Line Therapy in Treating Patients With Locally Advanced And/or Metastatic Transitional Cell Carcinoma of the Urothelium (SUCCINCT)Treatment
NCT00792025Sunitinib as Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Transitional Cell CancerTreatment
NCT00397488Sunitinib in Treating Patients With Progressive Metastatic Transitional Cell Cancer of the UrotheliumTreatment